{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-072408","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2026-06-10T21:01:03+00:00","discovered_at":"2026-06-10T21:02:00.235609+00:00","generated_at":"2026-06-10T21:02:12.117246+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Iovance's Amtagvi granted TGA approval in Australia for advanced melanoma","bullets":["Therapeutic Goods Administration of Australia approved Amtagvi for previously treated advanced melanoma.","Indicated for patients who received anti-PD-1 therapy and, if BRAF V600+, a BRAF/MEK inhibitor.","Third marketing authorization for Amtagvi; Iovance is authorizing its first Australian treatment center.","Australia has the world's highest melanoma rate, with ~17,000 new cases annually.","Approval based on Phase 2 C-144-01 trial results showing objective response rate and duration of response."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-072408","json":"https://secwatch.observer/filing/0001104659-26-072408.json","markdown":"https://secwatch.observer/filing/0001104659-26-072408.md","text":"https://secwatch.observer/filing/0001104659-26-072408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/0001104659-26-072408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/tm2613648d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:02:12.117246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}